“Advancing Patient-centered Care” in GPP: Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms, QofL
Spesolimab-sbzo (Spevigo, Boehringer Ingelheim) improves physical symptoms and lessens the mental health burden associated with generalized pustular psoriasis (GPP), according to post hoc exploratory analyses from the EFFISAYIL 2 clinical trial. The data were presented at the 2025 American Academy of Dermatology’s Annual Meeting in Orlando, FL. In EFFISAYIL 2, patients with a history of […]